Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C.

van der Eijk AA, Vrolijk JM, Haagmans BL.

N Engl J Med. 2006 Mar 23;354(12):1323-4. No abstract available.

2.

Weight-based versus fixed dosing of peginterferon (40kDa) alfa-2a.

Lamb MW, Martin NE.

Ann Pharmacother. 2002 May;36(5):933-5. No abstract available.

PMID:
12014351
3.

[Successful therapy with pegylated interferon alfa-2a. Hepatitis C patients remain virus-free].

[No authors listed]

MMW Fortschr Med. 2003 Sep 4;145(35-36):56. German. No abstract available.

PMID:
14584218
4.

Pegylated interferons.

Baker DE.

Rev Gastroenterol Disord. 2001;1(2):87-99. Review.

PMID:
12120178
5.

A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE).

Silva M, Poo J, Wagner F, Jackson M, Cutler D, Grace M, Bordens R, Cullen C, Harvey J, Laughlin M.

J Hepatol. 2006 Aug;45(2):204-13. Epub 2006 Apr 18.

PMID:
16780997
6.

Peginterferons in hepatitis C virus: virological, pharmacokinetic, and clinical implications. Introduction.

Keeffe EB.

Semin Liver Dis. 2003;23 Suppl 1:1-2. No abstract available.

PMID:
12934161
7.

Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C.

Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, Purdy S, Jansen PL, Zeuzem S.

Hepatology. 2007 Sep;46(3):640-8.

PMID:
17879366
8.

Treatment of chronic hepatitis C infection with peginterferons plus ribavirin.

Fried MW, Hadziyannis SJ.

Semin Liver Dis. 2004;24 Suppl 2:47-54. Review.

PMID:
15346246
9.

Neutralizing antibodies to interferon alpha in a chronic hepatitis C patient non-responder to pegylated interferon.

Santantonio T, Milella M, Antonelli G, Scagnolari C.

J Hepatol. 2006 Nov;45(5):759-61. Epub 2006 Sep 1. No abstract available.

PMID:
16979777
10.

Antiviral effect of peginterferon alfa-2b and alfa-2a compared.

Jansen PL, Reesink HW.

J Hepatol. 2006 Aug;45(2):172-3. Epub 2006 Jun 13. No abstract available.

PMID:
16797101
11.

Spotlight on peginterferon-alpha-2a (40KD) in chronic hepatitis C.

Perry CM, Jarvis B.

BioDrugs. 2002;16(3):213-7. Review.

PMID:
12102649
12.

Proceed with caution: peginterferon alpha-2a versus peginterferon alfa-2b in chronic hepatitis C. A systematic review of randomized trials.

Kershenobich D, Muñoz L, Malé R, Gaytan J, Sánchez F.

Hepatology. 2010 Dec;52(6):2240-1; author reply 2241-2. doi: 10.1002/hep.24025. No abstract available.

PMID:
21105116
13.

Pegylation of interferon alfa: structural and pharmacokinetic properties.

Pedder SC.

Semin Liver Dis. 2003;23 Suppl 1:19-22. Review.

PMID:
12934164
15.

[A 72 week follow-up study of chronic hepatitis C patients treated with peginterferon alfa-2b and ribavirin].

Yu SL, Zhang ZH, Lv H, Zhang QG, Wang YZ.

Zhonghua Gan Zang Bing Za Zhi. 2007 Mar;15(3):231. Chinese. No abstract available.

PMID:
17407724
16.

Peginterferon alfa-2a in patients with chronic hepatitis C.

Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ.

N Engl J Med. 2000 Dec 7;343(23):1666-72.

17.

Use of peginterferon alfa-2a (40 KD) (Pegasys) for the treatment of hepatitis C.

Rajender Reddy K, Modi MW, Pedder S.

Adv Drug Deliv Rev. 2002 Jun 17;54(4):571-86. Review.

PMID:
12052715
18.

[Treatment of chronic hepatitis C with peginterferon alpha-2a and the factors influencing the effect of this treatment].

Jin GD, Gong QM, Mao HJ, Xu DZ, Lu ZM.

Zhonghua Gan Zang Bing Za Zhi. 2005 Apr;13(4):302-4. Chinese. No abstract available.

PMID:
15850524
19.

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

Pijak MR, Gazdik F, Hrusovsky S.

Hepatology. 2004 Sep;40(3):760-1; author reply 761. No abstract available.

PMID:
15349918
20.

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C.

Rakov NE.

N Engl J Med. 2003 Jan 16;348(3):259-60; author reply 259-60. No abstract available.

Supplemental Content

Support Center